28 April 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Equity Incentive Plan Pool Increase and Grant of Share Options
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that the Company's Board of Directors has resolved to increase the pool for the granting of share options, restricted shares, and restricted share units under the Company's 2021 Equity Incentive Plan with Non-Employee Sub-Plan by 60,000,000 shares, amounting to a total pool of 90,000,000 shares.
The Company has also granted a total of 57,099,966 options over ordinary shares in the capital of the Company ("Share Options") to the Company's co-founder and CEO, Dr Vladislav Sandler. The Share Options vest in two tranches of 22,839,986 Share Options ("Tranche 1") and 34,259,980 Share Options ("Tranche 2"). The Tranche 1 Share Options are being granted in recognition of Dr Sandler's work in bringing HEMO-CAR-T to the point of preparing it for submission of an Investigational New Drug ("IND") application to the US Food and Drug Administration ("FDA") for approval. The Tranche 2 Share Options will vest upon authorization by the FDA for the Company to commence clinical trials of HEMO-CAR-T.
The details of the Share Options granted are set out below:
| Name | Position | Number of Share Options Granted | Exercise Price (pence) | Vesting Date/Criteria | Expiry Date |
| Dr Vladislav Sandler | CEO | 22,839,986
| Tranche 1: Tranche 2: | Tranche 1: immediately
Tranche 2: upon authorisation by the FDA to commence clinical trials of HEMO-CAR-T | Tranche 1: 27 April 2028 Tranche 2: 5 years from vesting date |
Following the grant of the Share Options, there are, in aggregate, 92,399,552 ordinary shares of 1 penny each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company arising from awards made under the Company's original Employee Plan, Non-Employee Plan and the 2021 Equity Incentive Plan with Non-Employee Sub-Plan. These represent 8.09% of the issued ordinary share capital of the Company.
Enquiries:
| Hemogenyx Pharmaceuticals plc | |
| Peter Redmond, Director | |
|
|
|
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):
| 1. | Details of PDMR/person closely associated with them | |||||
| a) | Name | Dr Vladislav Sandler | ||||
| b) | Position/status | CEO, Executive Director | ||||
| c) | Initial notification/ | Initial notification | ||||
| 2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument | Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc | ||||
| b) | Nature of the transaction | Grant of options | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
| ||||
| e) | Date of the transaction | 28/04/2023 | ||||
| f) | Place of the transaction | Outside of a trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
